Excellent Relapse-Free and Overall Survival in Pre-HCT Next-Generation Sequencing (NGS-MRD) Negative B-ALL Patients with or without TBI-Based Conditioning: Outcome of the Observational Arm of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) ONC1701 Endrad Study
Hisham Abdel‐Azim(University of Southern California), Michael A. Pulsipher(Primary Children's Hospital), Troy C. Quigg(CHRISTUS Transplant Institute), Niketa C. Shah, Emi Caywood(Alfred I. duPont Hospital for Children), Jeffrey S. Huo, Ulrich Duffner(Michigan United), Kris M. Mahadeo(Duke University), Benjamin Oshrine(Johns Hopkins All Children's Hospital), Elizabeth Gourdine, Rabi Hanna(Cleveland Clinic), Heather E. Stefanski(National Marrow Donor Program), Amy K. Keating(Boston Children's Hospital), Jemily Malvar(University of Southern California), Jodi Skiles(Indiana University School of Medicine), Dana Salzberg, Joseph H. Chewning(Kettering University), Nahal Lalefar(University of California, San Francisco), Jason Law(Michigan State University), Christine S. Higham(University of California, San Francisco), Lisa Madden(CHRISTUS Transplant Institute), Biljana Horn(UF Health Shands Hospital), Neena Kapoor(University of Southern California), Rachel Phelan(Children's Hospital of Wisconsin), Shalini Shenoy(Washington University in St. Louis), Barbara Bambach(Roswell Park Comprehensive Cancer Center), Leslie Lehmann(Harvard University)
Cited by 5
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
|Journal of Clinical Oncology|2022|369